Overview

Update
IPO / Stock
Went Public on Oct 8, 2015 / NASDAQ:CTMX
Total Equity Funding
$134.92M in 6 Rounds from 13 Investors
Headquarters:
Santa Barbara, CA
Description:
CytomX Therapeutics is an early-stage biotechnology company developing Probodies, proteolytically-activated antibodies.
Founders:
,
Categories:
Therapeutics, Health Care, Biotechnology
Website:
http://www.cytomx.com

Company Details

Update
Founded:
2008
Contact:
6503510353
Employees:
51 - 100 | 7 in Crunchbase

CytomX Therapeutics is an early stage, privately-funded biotechnology company developing Probodiesâ„¢, proteolytically-activated antibodies. Probodies, by their ability to site-direct the activity of antibodies, will result in an improved therapeutic index for validated targets as well enable the drugging of targets with broad tissue expression. Our mission, alone and with the help of partners, is to provide patients with more effective and less toxic therapies for severe illnesses such as cancer and inflammatory diseases.

Funding Rounds (6) - $134.92M

Update
DateAmount / RoundValuationLead InvestorInvestors
Jun, 2015$70M / Series D8
Jan, 2015$20M / Series C4
Apr, 2014$1.42M / Series B0
Jul, 2012$11M / Series B2
Sep, 2010$30M / Series B2
Mar, 2010$2.5M / Convertible Note1

Current Team (7)

Update

Offices/Locations (1)

Update
  • Office

    460 Ward Drive

    Suite E1

    Santa Barbara, CA 93111

    USA

Images (1)

Update

Add Acquisitions

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos